

# Leendert A Trouw

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/89143/leendert-a-trouw-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203  
papers

7,770  
citations

49  
h-index

81  
g-index

255  
ext. papers

8,907  
ext. citations

4.9  
avg, IF

5.9  
L-index

#	Paper	IF	Citations
203	B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100460	10.3	0
202	Circulating C1q levels in health and disease, more than just a biomarker. <i>Molecular Immunology</i> , <b>2021</b> , 140, 206-216	4.3	3
201	HLA-B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti-Carbamylated Protein Antibody-Positive/Anti-Cyclic Citrullinated Peptide-Negative Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 963-969	9.5	6
200	AB0113 ANTI-CARBAMYLATED PROTEIN ANTIBODIES POSITIVITY AND DISEASE ACTIVITY IN HISPANIC PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1085-1086	2.4	
199	Placental Complement Activation in Fetal and Neonatal Alloimmune Thrombocytopenia: An Observational Study. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
198	Anti-C1q autoantibodies may not serve as an adequate biomarker for lung manifestations in systemic sclerosis: a single-centre, cross-sectional study. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 657-658	4.8	
197	Auto-antibodies to post-translationally modified proteins in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , <b>2021</b> , 29, 924-933	6.2	2
196	Arthritis autoantibodies in individuals without rheumatoid arthritis: follow-up data from a Dutch population-based cohort (Lifelines). <i>Rheumatology</i> , <b>2021</b> , 60, 658-666	3.9	3
195	Autoantibodies are major predictors of arthritis development in patients with anti-citrullinated protein antibodies and musculoskeletal pain. <i>Scandinavian Journal of Rheumatology</i> , <b>2021</b> , 50, 189-197	1.9	4
194	Anti-carbamylated protein antibodies positivity and disease activity in Hispanic patients with established rheumatoid arthritis: An observational study. <i>Modern Rheumatology</i> , <b>2021</b> , 1-8	3.3	
193	Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 230	5.7	2
192	Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis?. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 146-150	2.2	
191	Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controls. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 570-577	2.2	3
190	Inverse correlation between serum complement component C1q levels and whole blood type-1 interferon signature in active tuberculosis and QuantiFERON-positive uveitis: implications for diagnosis. <i>Clinical and Translational Immunology</i> , <b>2020</b> , 9, e1196	6.8	1
189	Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. <i>Molecular Immunology</i> , <b>2020</b> , 120, 187-195	4.3	6
188	The role of complement activation in autoimmune liver disease. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102534	13.6	9
187	SAT0585 GEO-EPIDEMIOLOGY OF AUTOANTIBODIES IN RA: DIFFERENT PREVALENCES IN FOUR ETHNICALLY DIVERSE RA POPULATIONS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1251.1-1252	2.4	4

186	Complement component C1q is produced by isolated articular chondrocytes. <i>Osteoarthritis and Cartilage</i> , <b>2020</b> , 28, 675-684	6.2	9
185	Carbamylation reduces the capacity of IgG for hexamerization and complement activation. <i>Clinical and Experimental Immunology</i> , <b>2020</b> , 200, 1-11	6.2	4
184	Long-term follow-up of patients with anti-cyclic citrullinated peptide antibody-positive connective tissue disease: a retrospective observational study including information on the HLA-DRB1 allele and citrullination dependency. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 248	5.7	0
183	Systemic and pulmonary C1q as biomarker of progressive disease in experimental non-human primate tuberculosis. <i>Scientific Reports</i> , <b>2020</b> , 10, 6290	4.9	5
182	Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: response to the article by Regueiro et al. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 85	5.7	4
181	In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 28	5.7	18
180	Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 908-916	2.4	27
179	Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis. <i>Kidney International</i> , <b>2019</b> , 96, 738-749	9.9	7
178	Secretory form of rheumatoid arthritis-associated autoantibodies in serum are mainly of the IgM isotype, suggesting a continuous reactivation of autoantibody responses at mucosal surfaces. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 146-148	2.4	16
177	Complex medical history of a patient with a compound heterozygous mutation in. <i>Lupus</i> , <b>2019</b> , 28, 1255-1260	2.6	2
176	Complement activation and regulation in rheumatic disease. <i>Seminars in Immunology</i> , <b>2019</b> , 45, 101339	10.7	13
175	Screening for two or three autoantibodies in persons at risk for RA: implications of current data for clinical practice. <i>Rheumatology</i> , <b>2019</b> , 58, 914-915	3.9	2
174	Presence of Autoantibodies in Erosive Hand Osteoarthritis and Association with Clinical Presentation. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 101-105	4.1	7
173	The role of complement in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 3-8	5.3	4
172	Pitfalls in the detection of citrullination and carbamylation. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 136-141	13.6	23
171	Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 33	5.7	24
170	The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1087-1088	2.4	11
169	Complement Activation in Patients With Diabetic Nephropathy. <i>Kidney International Reports</i> , <b>2018</b> , 3, 302-313	4.1	23

168	Anti-Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis-A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 2096-2097	9.5	6
167	In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1836-1838	2.4	8
166	Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 94	5.7	7
165	Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2664	8.4	94
164	Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2427	8.4	24
163	Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1721-1731	9.5	55
162	The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching. <i>Rheumatology</i> , <b>2018</b> , 57, 1583-1591	3.9	9
161	The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 112-118	2.4	53
160	Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 716-720	2.4	24
159	Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , <b>2017</b> , 13, 331-339	8.1	74
158	Identification of Lifelines participants at high risk for development of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, e43	2.4	1
157	Production of complement components by cells of the immune system. <i>Clinical and Experimental Immunology</i> , <b>2017</b> , 188, 183-194	6.2	212
156	Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1184-1190	2.4	43
155	C1q-Dependent Dendritic Cell Cross-Presentation of In Vivo-Formed Antigen-Antibody Complexes. <i>Journal of Immunology</i> , <b>2017</b> , 198, 4235-4243	5.3	15
154	Breach of autoreactive B cell tolerance by post-translationally modified proteins. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1449-1457	2.4	20
153	The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 115	5.7	11
152	Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis. <i>Journal of Autoimmunity</i> , <b>2017</b> , 80, 77-84	15.5	28
151	Excretions/secretions from medicinal larvae ( <i>Lucilia sericata</i> ) inhibit complement activation by two mechanisms. <i>Wound Repair and Regeneration</i> , <b>2017</b> , 25, 41-50	3.6	10

150	The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia. <i>Rheumatology</i> , <b>2017</b> , 56, 2145-2153	3.9	33
149	The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 190	5.7	17
148	Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 246	5.7	11
147	Short article: Absence of serological rheumatoid arthritis biomarkers in inflammatory bowel disease patients with arthropathies. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 345-348	2.2	6
146	The complement system as a potential therapeutic target in rheumatic disease. <i>Nature Reviews Rheumatology</i> , <b>2017</b> , 13, 538-547	8.1	104
145	Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 1487-1492	3.9	18
144	Complement System <b>2017</b> , 355-365		
143	Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 285	8.4	36
142	Rheumatoid arthritis: Autoantibody testing to predict response to therapy in RA. <i>Nature Reviews Rheumatology</i> , <b>2016</b> , 12, 566-8	8.1	4
141	A5.09 Mri-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A44.3-A45	2.4	
140	A2.15 Ra phenotype at presentation differs among patients with few versus many autoantibodies. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A21.1-A21	2.4	
139	AB0066 MRI-Detected Osteitis Is Not Associated with The Presence or Level of ACPA Alone, but with The Combined Presence of ACPA and RF. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 919.2-920	2.4	
138	Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. <i>Lupus</i> , <b>2016</b> , 25, 878-88	2.6	21
137	Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 43	5.7	40
136	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 578-85	2.4	119
135	Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1924-1932	2.4	44
134	Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1139-44	2.4	33
133	FRI0337 anti-C1Q Autoantibodies, C1Q Circulating Immune Complexes and Complement Levels in Patients with Neuropsychiatric Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 556.3-557	2.4	

132	C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2016</b> , 7, 647	8.4	21
131	AB0086 Anti-Citrullinated Protein Antibodies in Patients with Cardiovascular Disease without RA. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 926.1-926	2.4	
130	A2.05 Carbamylated autoantigens facilitate the break of tolerance: A novel mechanism in the pathogenesis of autoimmune arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A17.1-A17	2.4	
129	Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 285	5.7	33
128	Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1575-6	2.4	30
127	A2.10 The isotype and subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A19.1-A19	2.4	
126	Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. <i>RMD Open</i> , <b>2016</b> , 2, e000172	5.9	13
125	MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 179	5.7	13
124	Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 289	5.7	32
123	The production and secretion of complement component C1q by human mast cells. <i>Molecular Immunology</i> , <b>2016</b> , 78, 164-170	4.3	20
122	Reply. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 2826-2827	9.5	1
121	Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 2090-8	9.5	30
120	Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 572-9	4.1	92
119	Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent. <i>Rheumatology</i> , <b>2015</b> , 54, 1930-2	3.9	21
118	Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. <i>Journal of Autoimmunity</i> , <b>2015</b> , 62, 39-44	15.5	27
117	Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 949-50	2.4	15
116	Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 25	5.7	90
115	Biomarkers for rheumatoid and psoriatic arthritis. <i>Clinical Immunology</i> , <b>2015</b> , 161, 2-10	9	37

114	A7.4 The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, A76.1-A76	2.4	
113	Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. <i>Lancet, The</i> , <b>2015</b> , 385 Suppl 1, S44	4.0	7
112	THU0040 In Rheumatoid Arthritis, Smoking is not Associated with Anti-Citrullinated Protein Antibodies (ACPA) Per SE, but with the Concurrent Presence of Rheumatoid Factor, Acpa and Anti-Carbamylated Protein Antibodies. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 206.4-207	2.4	
111	Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1786-93	4.1	20
110	Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 234-41	2.4	174
109	THU0114 Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate in the Avert Trial. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 234.3-235	2.4	2
108	Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis patients with mucosal inflammation: a case-control study. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 174	5.7	51
107	The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 339	5.7	55
106	Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 209	5.7	50
105	An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 276	5.7	16
104	Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 290ra87	17.5	223
103	Complement activation in Glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue. <i>Journal of Neuroimmunology</i> , <b>2015</b> , 278, 271-6	3.5	36
102	C1q, antibodies and anti-C1q autoantibodies. <i>Molecular Immunology</i> , <b>2015</b> , 68, 6-13	4.3	38
101	Identification of a novel non-coding mutation in C1qB in a Dutch child with C1q deficiency associated with recurrent infections. <i>Immunobiology</i> , <b>2015</b> , 220, 422-7	3.4	12
100	Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 270-6	2.4	33
99	Serum autoantibodies directed against transglutaminase-2 have a low avidity compared with alloantibodies against gliadin in coeliac disease. <i>Clinical and Experimental Immunology</i> , <b>2014</b> , 177, 86-93	6.2	4
98	Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 780-3	2.4	150
97	Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1761-8	2.4	92

96	A1.28 Anti-carp antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors and smoking. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A11.3-A12	2.4	
95	A1.29 In rheumatoid arthritis, smoking is not primarily associated with anti-citrullinated protein antibodies, but with the presence of several autoantibodies. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A12.1-A12	2.4	
94	A1.55 Development of antibodies specific for carbamylated protein precedes disease onset in MICE with collagen-induced arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A23.2-A24	2.4	
93	A1.45 Hyperglycosylation of ACPA-IGG variable domains modulates reactivity to citrullinated antigens. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A19.2-A19	2.4	
92	FRI0402 Cluster Analysis of an ARRAY of Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 532.3-533	2.4	
91	A1.49 Anti-carbamylated protein antibodies (ANTI-CARP) precede the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A21.1-A21	2.4	
90	Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 225-30	13.6	83
89	Antibodies specific for carbamylated proteins precede the onset of clinical symptoms in mice with collagen induced arthritis. <i>PLoS ONE</i> , <b>2014</b> , 9, e102163	3.7	29
88	Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1259-63	2.4	54
87	Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the 'AMC-Senshu' method. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 148-50	2.4	66
86	Autoimmunity in rheumatoid arthritis: different antigens--common principles. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72 Suppl 2, ii132-6	2.4	42
85	Autoantibodies against complement components and functional consequences. <i>Molecular Immunology</i> , <b>2013</b> , 56, 213-21	4.3	41
84	Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , <b>2013</b> , 173, 76-83	6.2	33
83	The concentration of anticitrullinated protein antibodies in serum and synovial fluid in relation to total immunoglobulin concentrations. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1059-63	2.4	17
82	AB0096 Presence of systemic arthritis autoantibodies in non-ra patients with severe periodontitis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A814.4-A815	2.4	1
81	Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 911-5		142
80	A5.4 Anti Carbamylated Protein Antibodies (Anti-CarP) Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A31.2-A31.4	2.4	2
79	Anti-C1q autoantibodies, novel tests, and clinical consequences. <i>Frontiers in Immunology</i> , <b>2013</b> , 4, 117	8.4	47



78	Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 2053-5	2.4	22
77	FRI0005 Production of anti-citrullinated protein antibodies by B cell subsets isolated from peripheral blood of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 312.2-312	2.4	24
76	A5.29 Spontaneous Production of Anti-Citrullinated Protein Antibodies in Cultures of Peripheral Blood Mononuclear Cells and Synovial Fluid Mononuclear Cells Isolated from Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A41.1-A41	2.4	
75	A5.6 Anti-Carbamylated Protein Antibodies are Present in Mice with Collagen induced Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A32.1-A32	2.4	
74	A5.14 Homocitrulline-Reactive Antibodies can be Generated from Synovial B-Cells from ACPA-Negative RA Patients. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A35.1-A35	2.4	1
73	The influence of ACPA status and characteristics on the course of RA. <i>Nature Reviews Rheumatology</i> , <b>2012</b> , 8, 144-52	8.1	144
72	Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. <i>Autoimmunity Reviews</i> , <b>2012</b> , 12, 318-22	13.6	103
71	Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R185	5.7	48
70	Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 1323-8		82
69	Novel genetic association of the VTCN1 region with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 567-71	2.4	11
68	The ACPA recognition profile and subgrouping of ACPA-positive RA patients. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 268-74	2.4	54
67	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 15-20	3.3	23
66	Genetic variants of C1q are a risk for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, A54.1-A54	2.4	
65	ACPA production by circulating B cells isolated from peripheral blood of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, A33.1-A33	2.4	2
64	The Benshu method often used to detect citrullinated proteins does not discriminate between citrullination and carbamylation. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, A40.2-A40	2.4	
63	The ACPA IgM fine specificity differs from the ACPA IgG antigen-recognition profile. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, A33.2-A33	2.4	
62	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 15-20	3.3	11
61	New biomarkers in rheumatoid arthritis. <i>Netherlands Journal of Medicine</i> , <b>2012</b> , 70, 392-9	0.5	26

60	Genetic association and functional consequences of a common SNP in the CD40 region with systemic lupus erythematosus and rheumatoid arthritis in a homogeneous Greek population. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, A14-A14	2.4	1
59	TRAF1/C5, eNOS, C1q, but not STAT4 and PTPN22 gene polymorphisms are associated with genetic susceptibility to systemic lupus erythematosus in Turkey. <i>Human Immunology</i> , <b>2011</b> , 72, 1210-3	2.3	38
58	The major risk alleles of age-related macular degeneration (AMD) in CFH do not play a major role in rheumatoid arthritis (RA). <i>Clinical and Experimental Immunology</i> , <b>2011</b> , 166, 333-7	6.2	8
57	Complement activation by (auto-) antibodies. <i>Molecular Immunology</i> , <b>2011</b> , 48, 1656-65	4.3	101
56	The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, R195	5.7	15
55	The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 1823-32		48
54	Role of complement in innate immunity and host defense. <i>Immunology Letters</i> , <b>2011</b> , 138, 35-7	4.1	51
53	The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1697-8	2.4	6
52	The major risk alleles of age related macular degeneration in CFH, do not play a major role in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, A17-A18	2.4	
51	Distinct ACPA fine-specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, A5-A5	2.4	
50	A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: implications for the pathogenesis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 2184-90	2.4	45
49	Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 188-93	2.4	100
48	Which elements of the criteria for RA are stable over time?. <i>Rheumatology</i> , <b>2011</b> , 50, 248-9	3.9	1
47	Genetic variants of C1q are a risk for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, A17-A17	2.4	2
46	Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 17372-7	11.5	385
45	The interaction between HLA SE alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, A1-A1	2.4	2
44	Low avidity anti-citrullinated protein antibodies (ACPA) are associated with high radiographic progression in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, A60-A60	2.4	
43	Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1461-4	2.4	39

42	Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 373-9	2.4	57
41	Anti-citrullinated protein antibodies have a low avidity compared to antibodies against recall-antigens. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, A7-A7	2.4	
40	Anti-CCP antibodies are a collection of ACPA that are cross-reactive to multiple citrullinated antigens. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, A8-A8	2.4	3
39	Analysis of binding sites on complement factor I that are required for its activity. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 6235-45	5.4	20
38	Infiltrating dendritic cells contribute to local synthesis of C1q in murine and human lupus nephritis. <i>Molecular Immunology</i> , <b>2010</b> , 47, 2129-37	4.3	42
37	Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. <i>European Journal of Immunology</i> , <b>2010</b> , 40, 172-85	6.1	48
36	C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activation. <i>Clinical Immunology</i> , <b>2010</b> , 135, 490-5	9	16
35	Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 1620-9		148
34	Both complement and IgG Fc receptors are required for development of attenuated antglomerular basement membrane nephritis in mice. <i>Journal of Immunology</i> , <b>2009</b> , 183, 3980-8	5.3	25
33	Genetic, molecular and functional analyses of complement factor I deficiency. <i>European Journal of Immunology</i> , <b>2009</b> , 39, 310-23	6.1	39
32	Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 1923-31		183
31	Complement inhibitor C4b-binding protein in primary Sjögren's syndrome and its association with other disease markers. <i>Scandinavian Journal of Immunology</i> , <b>2009</b> , 69, 374-80	3.4	22
30	Complement activation and inhibition: a delicate balance. <i>Trends in Immunology</i> , <b>2009</b> , 30, 83-90	14.4	262
29	Role of complement and complement regulators in the removal of apoptotic cells. <i>Molecular Immunology</i> , <b>2008</b> , 45, 1199-207	4.3	146
28	C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells. <i>Molecular Immunology</i> , <b>2008</b> , 45, 3649-60	4.3	40
27	Complement production and regulation by dendritic cells: molecular switches between tolerance and immunity. <i>Molecular Immunology</i> , <b>2008</b> , 45, 4064-72	4.3	32
26	Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. <i>Journal of Immunology</i> , <b>2008</b> , 180, 7613-21	5.3	113
25	C4b-binding protein is present in affected areas of myocardial infarction during the acute inflammatory phase and covers a larger area than C3. <i>PLoS ONE</i> , <b>2008</b> , 3, e2886	3.7	15

24	C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 28540-28548	5.4	104
23	The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 10894-900	5.4	107
22	A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. <i>Molecular Immunology</i> , <b>2007</b> , 44, 1835-44	4.3	68
21	Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation. <i>Molecular Immunology</i> , <b>2007</b> , 44, 3608-14	4.3	36
20	Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. <i>Journal of Immunology</i> , <b>2006</b> , 176, 7612-20	5.3	80
19	Activation of the lectin pathway in murine lupus nephritis. <i>Molecular Immunology</i> , <b>2005</b> , 42, 731-40	4.3	17
18	Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. <i>Kidney International</i> , <b>2005</b> , 68, 2091-102	9.9	41
17	Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. <i>American Journal of Transplantation</i> , <b>2005</b> , 5, 383-93	8.7	113
16	C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 201, 1937-48	16.6	75
15	A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. <i>British Journal of Rheumatology</i> , <b>2005</b> , 44, 111-9		47
14	Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. <i>Expert Opinion on Biological Therapy</i> , <b>2005</b> , 5, 243-51	5.4	27
13	The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 23869-73	5.4	64
12	Anti-C1q autoantibodies in murine lupus nephritis. <i>Clinical and Experimental Immunology</i> , <b>2004</b> , 135, 41-86.2		37
11	Maturation of dendritic cells abrogates C1q production in vivo and in vitro. <i>Blood</i> , <b>2004</b> , 103, 3813-20	2.2	129
10	Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 679-688	15.9	169
9	Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 679-88	15.9	63
8	Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2003</b> , 12, 619-24	3.5	77
7	Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. <i>Clinical and Experimental Immunology</i> , <b>2003</b> , 132, 32-9	6.2	51

6	Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. <i>Clinical and Experimental Immunology</i> , <b>2003</b> , 134, 335-43	6.2	51
5	Immune deposition of C1q and anti-C1q antibodies in the kidney is dependent on the presence of glomerular IgG. <i>Molecular Immunology</i> , <b>2003</b> , 40, 595-602	4.3	22
4	Complement and renal disease. <i>Molecular Immunology</i> , <b>2003</b> , 40, 125-34	4.3	23
3	Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. <i>European Journal of Immunology</i> , <b>2002</b> , 32, 1726-36	6.1	249
2	Specific inhibition of the classical complement pathway by C1q-binding peptides. <i>Journal of Immunology</i> , <b>2001</b> , 167, 7052-9	5.3	81
1	Autoantibodies to complement components. <i>Molecular Immunology</i> , <b>2001</b> , 38, 199-206	4.3	37